Congratulations to Madrigal Pharmaceuticals for achieving FDA approval for Rezdiffra (resmetirom)! The drug is indicated for adults with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. Several Velocity sites conducted these clinical trials across the U.S., and continue to support the rapidly advancing metabolism and endocrinology research. Nadege Gunn, MD, CPI, and Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, Velocity MASH CARE Council leaders, send their sincere appre

أمريكا توافق على أول دواء لعلاج شكل شائع من التهاب الكبد

A closer look at Rezdiffra, a new treatment for advanced fatty liver disease

Rezdiffra Access and Support Programs: Insights from Dr. Alkhouri | Fatty Liver Alliance posted on the topic | LinkedIn